Wilson's Disease (Hepatolenticular Degeneration)

Wilson's disease (hepatolenticular degeneration) is an autosomal recessive disorder of copper metabolism caused by pathogenic variants in ATP7B, a gene on chromosome 13q14.3 encoding a copper-transporting P-type ATPase expressed almost exclusively in hepatocytes.^[1] Normally, ATP7B does two jobs inside the liver cell: it loads copper onto newly synthesized apoceruloplasmin to form functional ceruloplasmin, and it pumps surplus copper across the hepatocyte's canalicular membrane into bile — the body's only meaningful route for excreting copper. When ATP7B is defective, both jobs fail together: ceruloplasmin synthesis and secretion falls (the basis of the classic low-ceruloplasmin finding), and biliary copper excretion collapses, so copper that would normally be exported instead accumulates inside hepatocytes.^[2]

Once hepatic copper-storage capacity is exceeded — which happens gradually over years — the excess spills into the bloodstream as non-ceruloplasmin-bound ("free") copper and redistributes to other organs, with a genuinely characteristic predilection for the brain (especially the basal ganglia) and the cornea, alongside ongoing hepatic injury. This dual organ pattern — liver and brain — is what makes Wilson's disease a classic, must-not-miss differential for two very different clinical scenarios in the same age group: a young patient with new, otherwise unexplained liver disease, and a young patient with new, otherwise unexplained neuropsychiatric or movement-disorder symptoms. Either presentation alone should prompt consideration of the diagnosis; a patient does not need both to have Wilson's disease.^[2][3]

Wilson's disease is rare but genuinely underdiagnosed relative to its true prevalence, which Liver Canada estimates at roughly 1 in 30,000 people, with an unaffected-carrier frequency of roughly 1 in 90.^[4] More than 700 pathogenic ATP7B variants have been described, with certain variants more common in specific ancestries — p.His1069Gln (H1069Q) is the most frequent pathogenic variant reported in patients of European ancestry, while p.Arg778Leu (R778L) predominates in East Asian populations — though most affected patients, especially outside these two variants, are compound heterozygotes rather than carrying the identical variant on both alleles.^[1] Onset is classically described between ages 5 and 35, but later presentations, including into the 50s and 60s, are increasingly recognized and should not be used to exclude the diagnosis on age alone.^[4][2]

Untreated, Wilson's disease is progressive and can be fatal — from decompensated liver disease, from acute liver failure (reported to carry 80-99% mortality without emergency liver transplantation), or from progressive neurologic disability.^[4] The encouraging counterpart to that severity is that Wilson's disease is one of the few genetic metabolic liver diseases for which effective, decades-proven lifelong pharmacotherapy exists — chelation and zinc, detailed in Choose Initial Treatment — and a patient diagnosed and treated before major organ damage can expect a normal or near-normal life expectancy.^[2]

Wilson's disease has no single typical presentation — it can appear anywhere along a spectrum from asymptomatic biochemical liver-test abnormality to fulminant liver failure, and separately, anywhere along a spectrum from a subtle personality change to a florid movement disorder. Recognizing the pattern, rather than waiting for a specific combination of findings, is what actually catches the diagnosis while it is still fully treatable.

• Autosomal recessive inheritance of pathogenic ATP7B variants — both gene copies must carry a pathogenic variant for clinical disease; parents of an affected patient are typically asymptomatic heterozygous carriers.^[1]
• A first-degree relative, especially a sibling, of a confirmed patient — because of autosomal recessive inheritance, each sibling of an affected patient has a 25% chance of also being affected, a 50% chance of being an unaffected carrier, and a 25% chance of inheriting neither variant; this is the single strongest reason to test even a completely asymptomatic sibling (see Non-Pharmacologic Treatment).^[2]
• Consanguinity in the family, which increases the likelihood both parents carry the same or a complementary pathogenic variant.
• Certain ancestries carry specific common founder variants, though Wilson's disease occurs across all populations and ancestry alone should never be used to exclude the diagnosis: p.His1069Gln is most common in patients of European ancestry, and p.Arg778Leu is most common in East Asian populations.^[1]
• Age under roughly 40 with unexplained liver disease, or age under roughly 40 with a new, otherwise unexplained movement disorder or psychiatric illness — not a population risk factor in the usual sense, but the two clinical scenarios that should specifically trigger consideration of the diagnosis (see Recognize the Condition).
• No significant environmental, dietary, or acquired risk factor increases susceptibility to Wilson's disease itself — unlike some other genetic liver conditions, disease expression is driven by the underlying genotype rather than by lifestyle cofactors, though alcohol use and other liver insults can still worsen hepatic injury once Wilson's disease is present.

Complications of undiagnosed or inadequately treated Wilson's disease

Left undiagnosed or inadequately treated, Wilson's disease can progress to decompensated cirrhosis, acute (fulminant) liver failure, permanent neurologic disability, or death. Unlike many chronic liver diseases, a substantial fraction of first presentations are already severe — acute liver failure is a recognized initial presentation, not only a late complication of a previously known diagnosis.^[2]

Timing is, again, the single biggest determinant of outcome. Wilson's disease diagnosed and treated before cirrhosis or significant neurologic injury develops carries an excellent prognosis; established cirrhosis and neurologic damage present for a prolonged period are considerably less likely to fully reverse even with adequate copper-reduction therapy — which is why a patient's own adherence to lifelong treatment (see Choose Initial Treatment) matters just as much as the initial time-to-diagnosis.^[2][3]

No single test is perfectly sensitive and specific for Wilson's disease, which is why diagnosis is built from a combination of biochemical, ophthalmologic, histologic, and increasingly genetic findings rather than any one result in isolation.^[2][3]

Step 1 — serum ceruloplasmin

A low serum ceruloplasmin (generally under 20 mg/dL, or under 0.2 g/L) supports the diagnosis and is usually the first test ordered, but it is neither sensitive nor specific enough to stand alone. Ceruloplasmin is an acute-phase reactant and can be falsely normal in inflammation, pregnancy, and estrogen therapy — and, importantly, in a meaningful minority of Wilson's disease patients themselves, particularly those with a neurologic-predominant presentation; a normal ceruloplasmin does not exclude the diagnosis in a patient with a compatible clinical picture. Conversely, a low ceruloplasmin is not specific to Wilson's disease and also occurs in malnutrition, protein-losing states (nephrotic syndrome, protein-losing enteropathy), and end-stage liver disease of any cause.^[2]

Step 2 — 24-hour urinary copper excretion

An elevated 24-hour urinary copper — generally over 100 mcg/24h (over 1.6 micromol/24h) in a symptomatic patient, against a normal range under roughly 40 mcg/24h — reflects the free, non-ceruloplasmin-bound copper the kidney is filtering, and is one of the more useful diagnostic tests. In children, or in borderline cases, a penicillamine challenge test (measuring urinary copper excretion after a test dose of penicillamine) can help clarify an ambiguous baseline result. This same 24-hour urinary copper measurement becomes the primary tool used to confirm adequate chelator dosing once treatment starts — see Choose Initial Treatment.^[2][3]

Step 3 — slit-lamp examination for Kayser-Fleischer rings

Requires a formal slit-lamp exam, not a routine visual inspection — an easy point to miss if ophthalmology or optometry referral is not specifically requested. As noted in Recognize the Condition, presence strongly supports the diagnosis, especially with neurologic symptoms, but a meaningful proportion of purely hepatic presentations lack rings entirely, so absence does not rule Wilson's disease out.^[2]

Step 4 — liver biopsy with hepatic copper quantification

Reserved for genuine diagnostic uncertainty after the above — for example, a compatible clinical picture with a normal ceruloplasmin and equivocal urinary copper. A quantitative hepatic copper concentration over roughly 250 mcg/g dry weight supports the diagnosis (normal is under about 50 mcg/g dry weight), though copper deposition can be patchy, especially in a cirrhotic liver, so a normal result on a single biopsy sample does not fully exclude the diagnosis if suspicion remains high.^[2]

Step 5 — ATP7B genetic testing

Full-gene sequencing can identify the causative variants directly and is increasingly used both to confirm an equivocal biochemical/clinical diagnosis and — critically — to enable fast, definitive cascade testing of at-risk siblings once an index patient's variants are known (see Non-Pharmacologic Treatment).^[1]

Putting it together — the Leipzig scoring system

A total score of 4 or more establishes the diagnosis; a score of 2-3 makes it possible and warrants further testing; a score under 2 makes it unlikely.^[2][3]

Differential diagnosis

Before attributing unexplained liver disease in a young patient to Wilson's disease, still consider autoimmune hepatitis, viral hepatitis, alcohol-related liver disease, and metabolic dysfunction-associated steatotic liver disease — and remember these are not mutually exclusive with Wilson's disease, which can itself produce a steatotic- or autoimmune-hepatitis-like histologic picture. For a new movement disorder or psychiatric presentation, the differential includes primary psychiatric illness and other inherited movement disorders — and, worth naming for contrast, Menkes disease, a different and much rarer X-linked disorder of a related copper-transport gene (ATP7A) that causes copper deficiency rather than overload, with an essentially opposite clinical picture.

Family cascade testing

Once an index patient is confirmed, every first-degree relative — particularly siblings — should be offered testing (ceruloplasmin, 24-hour urinary copper, and ATP7B genetic testing where the index patient's variants are known) even if completely asymptomatic, because presymptomatic diagnosis changes first-line treatment entirely (see Choose Initial Treatment).^[2]

• Achieve a negative copper balance and normalize non-ceruloplasmin-bound ("free") copper — the specific chelation dosing and monitoring approach is detailed in Choose Initial Treatment.
• Prevent, halt, or — where still possible — allow partial reversal of hepatic and neurologic copper-related injury.
• In a neurologically or psychiatrically affected patient: achieve adequate decoppering without provoking paradoxical neurologic worsening from too-rapid initial chelation — a genuinely important, specific goal covered in depth in Choose Initial Treatment.
• Sustain treatment indefinitely — Wilson's disease has no cure short of liver transplantation, and treatment discontinuation at any point allows copper to reaccumulate, which is why lifelong adherence is itself a primary treatment target, not merely a footnote (see Choose Initial Treatment and Common Errors to Avoid).
• For a presymptomatic, family-screening-identified patient: prevent copper accumulation from ever becoming clinically significant, generally with zinc rather than chelation (see Choose Initial Treatment).
• Avoid over-treatment — driving copper too low with chelation therapy causes its own toxicity (see Monitoring & Follow-Up) and is not itself a treatment goal.
• Complete first-degree relative cascade testing.
• For decompensated cirrhosis or acute liver failure unresponsive to medical management: timely liver transplant evaluation, which is curative for the hepatic manifestation of the disease (see Special Populations and Treatment Failure/Next Step).

D-penicillamine versus trientine — choosing a chelator

Both agents chelate copper directly and promote its urinary excretion, and both are guideline-endorsed, effective first-line options — the choice between them is driven almost entirely by their genuinely different adverse-effect profiles rather than by any meaningful difference in efficacy.^[2][3]

D-penicillamine, the original agent introduced in the 1950s, carries a substantially higher burden of both early and late adverse effects. Early hypersensitivity reactions — fever, rash, lymphadenopathy, proteinuria — occur in a meaningful minority of patients within the first few weeks and are its single most common reason for discontinuation. Later, idiosyncratic reactions include membranous nephropathy with nephrotic-range proteinuria, a lupus-like syndrome, a myasthenia gravis-like syndrome, elastosis perforans serpiginosa, and rarely aplastic anemia or agranulocytosis. Penicillamine is also a pyridoxine (vitamin B6) antagonist, which is why pyridoxine supplementation is specifically required alongside it — an easy, important point to lose track of (see Drug Tables).^[2]

Trientine is chemically distinct but works by the same broad mechanism, and a large FDA Adverse Event Reporting System pharmacovigilance analysis found a materially better tolerability profile: penicillamine treatment was discontinued for adverse events in 28.8% of reported cases, versus 7.1% for trientine, with hypersensitivity dominating the penicillamine adverse-event signal against a milder, more gastrointestinal-predominant pattern (abdominal pain, nausea) for trientine.^[5] This genuinely better tolerability, alongside trientine not requiring pyridoxine supplementation, is a real, specific reason trientine has become preferred first-line therapy in more recent guidance, including the 2024 EASL-ERN clinical practice guidelines, while penicillamine remains an effective, guideline-endorsed alternative, particularly where cost or access favor it.^[3]

The paradoxical neurologic worsening risk — and why initial dosing strategy matters

This is the single most important safety point in initiating chelation therapy. In patients with neurologic or psychiatric Wilson's disease, starting a chelator — historically described most with penicillamine, though not exclusively — can cause a genuine paradoxical worsening of neurologic symptoms within the first weeks to months of treatment, reported across a wide range in different studies (commonly cited figures cluster around 10-25% of neurologically affected patients, with some series reporting worsening in as many as half). The proposed mechanism is that rapid chelator-driven mobilization of copper out of hepatic stores transiently raises non-ceruloplasmin-bound ("free") copper in the bloodstream faster than it can be excreted, and this free copper redistributes further into an already copper-laden brain before net whole-body copper begins to fall. Critically, worsening from this mechanism is not always fully reversible even once copper burden subsequently normalizes.^[2][3]

Initiation and monitoring protocol

Obtain a baseline 24-hour urinary copper before starting therapy. After initiating or adjusting a chelator dose, recheck 24-hour urinary copper approximately 4-6 weeks later: during active decoppering, urinary copper should rise substantially above baseline (often into the several-hundred to over-1000 mcg/24h range) as the chelator successfully mobilizes and excretes stored tissue copper — a urinary copper that fails to rise appropriately should prompt review of adherence or a dose increase rather than an assumption that chelation has failed.^[2]

Titrate the chelator dose upward, alongside routine safety monitoring (complete blood count, urinalysis for proteinuria, and liver enzymes — detailed further in Monitoring & Follow-Up), until the patient reaches a maintenance dose with adequate ongoing urinary copper excretion and clinical stability. D-penicillamine is typically taken on an empty stomach (at least one hour before or two hours after meals) to maximize absorption and avoid mineral/food chelation interactions; trientine follows the same empty-stomach principle.^[2]

Avoiding over-chelation

More copper removal is not always better. Once decoppering is well established, continued full-dose chelation can drive the body into a genuine copper-deficient state, which has its own distinct toxicity — sideroblastic anemia, leukopenia, and a demyelinating myeloneuropathy that can mimic subacute combined degeneration. Monitoring during the maintenance phase (see Monitoring & Follow-Up) is specifically designed to catch this before it becomes symptomatic, and dose reduction — often with a switch toward maintenance-phase zinc — is the usual response once adequate long-term decoppering is confirmed.^[2]

Zinc — a genuinely different mechanism, for a genuinely different role

Zinc does not chelate copper. Its mechanism is entirely different: oral zinc induces metallothionein, a copper-binding protein, in the cells lining the small intestine. Metallothionein binds dietary copper (and the copper the body itself resecretes into saliva and gastric juice) inside these enterocytes, and the bound copper is then lost in stool as the intestinal lining sheds and renews itself over its normal several-day turnover, rather than being absorbed into the bloodstream at all. The practical effect is a slow, steady reduction in net copper absorption rather than active removal of copper already in the body — which is exactly why zinc is far too slow to be appropriate initial monotherapy for a newly symptomatic patient with an existing copper burden, but is well suited to its two actual roles: maintenance therapy after a chelator has already achieved adequate decoppering, and first-line initial therapy for presymptomatic patients identified through family screening, where there is no existing burden to remove — only future accumulation to prevent.^[2][3]

Typical adult dosing is zinc acetate 50 mg elemental zinc three times daily, taken on an empty stomach and separated from food by at least an hour, since food significantly reduces absorption. The most common adverse effect is gastrointestinal irritation/gastritis, which is dose-limiting for some patients. Zinc and a chelator are generally not combined routinely as first-line therapy for a newly symptomatic patient — if used together in a specialist-directed situation, doses must be separated by several hours, since taken together they can reduce each other's absorption and effectiveness.^[2]

Lifelong therapy — the single highest-stakes adherence point in this chapter

Wilson's disease requires treatment for life, with no defined endpoint. The underlying ATP7B defect is present in every hepatocyte outside a transplanted liver, so copper reaccumulates as soon as effective treatment stops — including after years of apparent stability with normalized copper studies. Reported relapses after treatment discontinuation include acute liver failure, sometimes fatal, in patients who had previously responded well to therapy. This is not a theoretical risk: nonadherence clusters specifically around the transition from pediatric to independent adult care, when a clinically well-feeling young adult can be tempted to stop medication that no longer feels necessary — a period worth flagging explicitly at every visit during that transition (see Special Populations and Non-Pharmacologic Treatment).^[2][3]

Dietary copper restriction

An adjunct, never a substitute for pharmacotherapy. Advise avoiding or minimizing high-copper foods, particularly during at least the first year of treatment: liver and other organ meats, shellfish (oysters, lobster, crab), nuts, chocolate/cocoa, mushrooms, and dried fruits and legumes. Some guidance allows dietary restriction to relax somewhat once a patient is clinically stable on established maintenance therapy, since the medication does most of the work by that point — but this should be an individualized decision made with the treating specialist rather than a default.^[4][2]

Ask specifically about drinking-water source and household plumbing — well water or water that has sat in copper pipes, particularly if the water is soft or acidic, can be a genuinely overlooked source of dietary copper worth identifying at diagnosis. Advise against cooking or storing food in copper cookware.

Alcohol counseling

Advise limiting or avoiding alcohol — it adds an independent hepatotoxic burden to a liver already under copper-related stress and can accelerate progression to fibrosis, particularly before treatment has achieved adequate decoppering.

Patient education and adherence

Set clear expectations at diagnosis that treatment is lifelong with no natural stopping point, and that stopping — even years later, even after normalization of copper studies — risks a serious, potentially fatal relapse (see Choose Initial Treatment). This is worth restating explicitly, and repeatedly, during the transition from pediatric to adult care, a described high-risk period for silent nonadherence in a patient who otherwise feels completely well.^[2]

Liver Canada provides patient-facing information and a toll-free support line (1-800-563-5483) worth mentioning directly to a newly diagnosed Canadian patient and family, alongside genetic counseling referral where available.^[4]

Family cascade screening

Wilson's disease is inherited in an autosomal recessive pattern. Every first-degree relative of a confirmed patient — siblings in particular — should be offered testing (ceruloplasmin, 24-hour urinary copper, and, once the index patient's variants are known, direct ATP7B genetic testing) regardless of whether they have any symptoms, since each sibling carries a 25% a priori chance of also being affected.^[2] Counsel that a presymptomatic relative who tests positive benefits enormously from early identification — presymptomatic disease is treated with zinc rather than chelation and, started before any organ damage occurs, carries an excellent prognosis (see Choose Initial Treatment).

Pregnancy

Treatment must continue throughout pregnancy — stopping risks a maternal hepatic relapse that can be severe. Chelation is generally continued, typically at a reduced dose during pregnancy under specialist direction, given some historical teratogenicity concern with high-dose penicillamine; trientine and zinc are also used and considered options during pregnancy under specialist care. This is a treating-specialist decision made individually rather than a default agent switch, and preconception counseling with the treating hepatologist/specialist is worth encouraging for any patient of childbearing potential.^[2][3]

Breastfeeding

Zinc is generally considered compatible with breastfeeding. Data on chelator safety during breastfeeding are more limited; this is a shared decision with the treating specialist, individualized to the specific agent and dose in use.

Pediatrics

Wilson's disease commonly presents in childhood and adolescence, most often with hepatic findings, and pediatric dosing of all agents is weight-based per the product monograph. The transition from pediatric to adult care is a specifically described high-risk period for nonadherence in an otherwise well-feeling young adult (see Choose Initial Treatment and Non-Pharmacologic Treatment) and deserves explicit, structured attention rather than an assumption that a previously stable pediatric patient will simply continue treatment independently.^[2]

Presymptomatic patients identified by family screening

Managed differently from the start: zinc, not chelation, is the appropriate first-line therapy, since there is no existing copper burden requiring active mobilization — only future accumulation to prevent (see Choose Initial Treatment). Ongoing monitoring is still required for life; presymptomatic status at diagnosis does not mean monitoring or treatment can ever be safely stopped.

Renal impairment

Penicillamine-associated nephrotic syndrome (see Choose Initial Treatment and Drug Tables) requires specific vigilance with urinalysis monitoring; new significant proteinuria on penicillamine should prompt specialist reassessment and consideration of switching to trientine.

Decompensated cirrhosis or acute liver failure

See Treatment Failure/Next Step and Red Flags & Refer — this population needs urgent hepatology involvement and formal transplant-eligibility scoring rather than routine outpatient chelation initiation and titration.

• Initiation/titration phase (any chelator): 24-hour urinary copper approximately 4-6 weeks after starting or changing dose, to confirm adequate mobilization (see Choose Initial Treatment); complete blood count and urinalysis for proteinuria at baseline and periodically during titration, particularly for penicillamine given its nephrotoxicity/hematologic risk; liver enzymes periodically.^[2]
• D-penicillamine specifically: watch closely for hypersensitivity signs (fever, rash, lymphadenopathy) in the first several weeks; confirm pyridoxine is co-prescribed and continued.
• Maintenance phase: 24-hour urinary copper and a calculated non-ceruloplasmin-bound ("free") serum copper — total serum copper minus (3 × ceruloplasmin in mg/dL) — approximately every 6-12 months once stable, aiming for a free copper generally in the range of roughly 50-150 mcg/L: high enough to confirm treatment has not lapsed, low enough to avoid over-chelation.^[2]
• Watch specifically for over-chelation: new unexplained cytopenias or myelopathy symptoms in a patient on long-term chelation should prompt a copper-deficiency workup and dose reduction, often with transition toward zinc maintenance (see Choose Initial Treatment).
• Neurologic/psychiatric status: reassess at each visit, especially in the first months of chelation, specifically distinguishing expected slow improvement from paradoxical treatment-related worsening (see Choose Initial Treatment and Treatment Failure/Next Step).
• Hepatic status: periodic liver enzymes and, for a patient with cirrhosis at diagnosis, the same ongoing hepatocellular carcinoma and portal-hypertension surveillance used for cirrhosis of any cause.
• Adherence, specifically, at every visit — given the fatal-relapse stakes of treatment discontinuation, adherence deserves as much explicit, repeated attention as the lab values themselves, particularly through the pediatric-to-adult care transition.
• Confirm first-degree relative cascade testing has actually been completed, not only discussed once and left open.

1. Neurologic symptoms worsening after starting chelation: first distinguish paradoxical treatment-related worsening (typically within the first weeks to months, from rapid free-copper mobilization) from disease progression due to inadequate treatment or nonadherence — review the urinary copper trend and adherence history rather than assuming either cause by default. If paradoxical worsening is confirmed or strongly suspected, slow the titration further and consider specialist-directed dose reduction or a chelator switch; do not simply stop treatment altogether, since untreated disease also progresses.^[2]
2. Urinary copper not rising as expected after starting or increasing a chelator dose: confirm adherence before increasing the dose further or assuming the chelator has failed — nonadherence is common and easy to miss in a patient who otherwise appears engaged in care.
3. Hypersensitivity reaction to penicillamine: stop penicillamine; depending on severity, a switch to trientine is generally preferred over attempting penicillamine desensitization, given trientine's substantially better tolerability profile.^[5]
4. New significant proteinuria on penicillamine: evaluate for penicillamine-induced membranous nephropathy; switch to trientine under specialist direction if confirmed or strongly suspected.
5. New unexplained cytopenias or myelopathy on long-term chelation: evaluate for over-chelation/copper deficiency (see Monitoring & Follow-Up) rather than assuming an unrelated cause; reduce chelator dose and involve the treating specialist.
6. Decompensated cirrhosis or acute liver failure despite treatment, or as an initial presentation: urgent hepatology referral for transplant-eligibility scoring (see Special Populations) — pharmacologic decoppering alone will not reverse established acute liver failure quickly enough to be the sole strategy in this setting.^[2][4]
7. Apparent relapse after a period of treatment discontinuation: treat as a medical emergency-in-waiting — reinstitute therapy immediately and monitor closely, since discontinuation-related relapse has a genuine risk of proceeding to fatal acute liver failure even in a patient with a previously excellent response to treatment (see Choose Initial Treatment).^[2]

• Excluding Wilson's disease because serum ceruloplasmin is normal — a normal ceruloplasmin does not rule out the diagnosis, particularly in a neurologic-predominant presentation (see Assessment & Diagnosis).^[2]
• Excluding Wilson's disease because Kayser-Fleischer rings are absent, particularly in a hepatic-predominant presentation, where a meaningful minority of confirmed patients never develop rings at all.^[2]
• Attributing a young patient's new liver disease, or new psychiatric/movement-disorder presentation, entirely to a more common alternative diagnosis without ever considering Wilson's disease as at least part of the differential (see Recognize the Condition).
• Starting a chelator at full maintenance dose immediately in a neurologically or psychiatrically affected patient, rather than titrating gradually — a real, specific way to precipitate paradoxical neurologic worsening (see Choose Initial Treatment).
• Prescribing D-penicillamine without concomitant pyridoxine.
• Using zinc as sole initial therapy for a newly diagnosed, symptomatic patient with an existing significant copper burden — zinc is too slow, and this delay can allow ongoing organ injury.
• Combining zinc and a chelator on the same schedule without separating doses, or combining them routinely without a specific reason to do so.
• Allowing a gap in treatment — especially during the transition from pediatric to adult care — under the assumption that a clinically well patient no longer needs medication; this is a genuinely high-stakes, described cause of fatal relapse (see Choose Initial Treatment).
• Continuing full-dose chelation indefinitely without monitoring for over-chelation/copper deficiency once adequate decoppering has been achieved.
• Not offering testing to asymptomatic first-degree relatives, particularly siblings, of a confirmed patient.

How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.

Copper Chelation Therapy — First-Line for Symptomatic Disease

Both agents are guideline-endorsed first-line chelators; the choice between them is driven mainly by comparative tolerability. In neurologically or psychiatrically affected patients, initiate cautiously with gradual up-titration to reduce paradoxical neurologic worsening risk. Doses are adult doses and require patient-specific, product-monograph-confirmed titration.

Zinc Therapy — Presymptomatic and Maintenance Treatment

A fundamentally different mechanism from chelation: reduces intestinal copper absorption via enterocyte metallothionein induction rather than mobilizing and excreting existing copper stores. Too slow for initial monotherapy of a newly symptomatic patient with significant existing copper burden.

Required Adjunct

What to Avoid

Confirm neither is being taken, including inadvertently through a routine multivitamin, at every medication review.